Telomir CFO files initial insider Form 3
Telomir Pharmaceuticals, Inc. filed an initial ownership report for Chief Financial Officer Andriy Mushak.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Telomir Pharmaceuticals, Inc. filed an initial ownership report for Chief Financial Officer Andriy Mushak. This Form 3 shows his status as an officer but does not list any common stock or derivative security transactions or holdings at the time of the filing.
Key Figures
Buy transactions: 0 shares
Sell transactions: 0 shares
Derivative exercises: 0 shares
+2 more
5 metrics
Buy transactions
0 shares
Form 3 transactionSummary buyShares
Sell transactions
0 shares
Form 3 transactionSummary sellShares
Derivative exercises
0 shares
Form 3 transactionSummary exerciseShares
Gifted shares
0 shares
Form 3 transactionSummary giftShares
Net buy/sell direction
neutral
Form 3 transactionSummary netBuySellDirection
Key Terms
Form 3, Chief Financial Officer, insider ownership
3 terms
Form 3 regulatory
"This Form 3 shows his status as an officer but does not list any transactions."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Chief Financial Officer financial
"filed an initial ownership report for Chief Financial Officer Andriy Mushak."
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
insider ownership financial
"It functions as an initial ownership statement related to insider ownership reporting."
The percentage of a company’s stock held by people with access to inside information or control, typically officers, directors and large shareholders who work at or help run the business. It matters to investors because it shows how much “skin in the game” insiders have and can signal alignment of interests, potential for concentrated control, and effects on share liquidity—like neighbors owning most of a street, which changes how decisions are made and how easy it is for others to move in or out.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Telomir Pharmaceuticals (TELO) Form 3 for Andriy Mushak show?
The Form 3 for Andriy Mushak reports his position as Chief Financial Officer of Telomir Pharmaceuticals. It functions as an initial ownership statement and indicates no reported common stock or derivative security transactions or holdings at the time of this filing.
Is Telomir Pharmaceuticals CFO Andriy Mushak buying or selling TELO stock in this Form 3?
No stock purchases or sales are reported for Andriy Mushak in this Form 3. The filing is an initial ownership statement and shows zero buy, sell, acquire, dispose, gift, tax withholding, or restructuring share activity in the summarized data.
Does the TELO Form 3 for CFO Andriy Mushak include any option or warrant exercises?
The Form 3 summary indicates no option or warrant exercises for Andriy Mushak. Exercise-related fields such as exerciseCount and exerciseShares are zero, and the derivativeSummary section contains no listed derivative positions or transactions in this filing.
What insider activity counts are disclosed for TELO CFO Andriy Mushak?
The filing shows zero counts for buying, selling, acquiring, disposing, gifts, tax withholding, restructuring, and derivative transactions. Net buy-sell direction is listed as neutral, and holdingEntries are also zero in the transactionSummary section for this Form 3.
What role does Andriy Mushak hold at Telomir Pharmaceuticals in this Form 3?
Andriy Mushak is identified as an officer of Telomir Pharmaceuticals in the Form 3. His specific title is Chief Financial Officer, and he is not reported as a director or ten percent owner according to the role indicators included in the filing data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
